The Hippo-YAP pathway is an emerging signalling cascade involved in the regulation of stem cell activity and organ size. To identify components of this pathway, we performed an RNAi-based kinome screen in human cells. Our screen identified several kinases not previously associated with Hippo signalling that control multiple cellular processes. One of the hits, LKB1, is a common tumour suppressor whose mechanism of action is only partially understood. We demonstrate that LKB1 acts through its substrates of the microtubule affinity-regulating kinase family to regulate the localization of the polarity determinant Scribble and the activity of the core Hippo kinases. Our data also indicate that YAP is functionally important for the tumour suppressive effects of LKB1. Our results identify a signalling axis that links YAP activation with LKB1 mutations, and have implications for the treatment of LKB1-mutant human malignancies. In addition, our findings provide insight into upstream signals of the Hippo-YAP signalling cascade.
epithelial malignancies [7] [8] [9] . However, genomic analyses of common epithelial cancers have not revealed a significant rate of mutations in the known components of the pathway 10 . Recent data also suggest the presence of alternative kinases that might be responsible for YAP regulation 9, 11 . Thus, common alterations of Hippo signalling in human cancer might be caused by mutations in genes not associated with the pathway at present.
Here, we have performed a genetic screen to identify kinases that impinge on the Hippo pathway. Our work uncovers kinases associated with multiple aspects of cellular function that are robust regulators of YAP localization and activity. These data provide important insight about the nature of inputs that speak to Hippo kinases. In addition, we identify the tumour suppressor LKB1 and its substrates of the microtubule affinity-regulating kinase (MARK) family as crucial regulators of the Hippo pathway. We present functional evidence suggesting that YAP is a critical component of the LKB1 tumour suppressive pathway. Our data have significant implications for the treatment of Lkb1-mutant cancers. 
A R T I C L E S
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Relative fold change Fluorescence intensity was captured by flow cytometry. Statistical analysis was performed to identify genes for secondary screening and final selection of hits. (d) Mean Z -score and mCherry reporter fold change (versus scrambled controls) values for each triplicate siRNA oligonucleotide were plotted to identify hits with statistical thresholds of Z -score >2 and fold change greater than 4. Highlighted rectangle represents hits satisfying these thresholds. Green filled circles represent siRNA knockdown of LATS2 as a positive control. (e) A secondary siRNA screen identifies kinases that reproducibly raise STBS-mCherry reporter activity, performed using an alternative siRNA oligonucleotide source using two reporter systems. The secondary screen was repeated three times using pooled siRNAs. 
RESULTS
A genetic screen identifies multiple Hippo-regulating kinases
To identify potential kinases that can repress YAP/TEAD activity, we developed an improved transcriptional reporter containing 14 copies of the known TEAD DNA-binding sequence (SuperTBS reporter; Fig. 1a ) 11 . Functional assays revealed that this reporter faithfully recapitulated YAP/TEAD transcriptional activity, and was highly responsive to perturbations of endogenous upstream Hippo components such as LATS2 and the cytoskeleton-associated protein NF2 (refs 12, 13 and Fig. 1b) . Armed with a robust reporter for Hippo-YAP activity, we interrogated the effects of a human kinome short interfering RNA (siRNA) library containing 2,130 unique 0   2   4   6   8   10   12   14   MARK1  MARK2  MARK3  MARK4  PRKAA1  PRKAA2  PRKAB1  PRKAB2  PRKAG1  PRKAG2  PRKAG3  SNRK1  SNRK2  KSR1  NUAK1  NUAK2  BRSK1  BRSK2  SIK  mTOR  CTR siRNA oligonucleotides for 710 kinase genes in a HEK293T cell line stably carrying the reporter (Fig. 1c) . Initial hits were identified by a statistical Z -score cutoff of 2 in addition to a >4-fold change of mean fluorescence intensity compared with scrambled siRNA controls (Fig. 1d) . Our high-stringency statistical analysis revealed 21 kinases whose silencing resulted in enhanced STBS reporter activity ( Fig. 1d and Supplementary Table 1) . Through a secondary screen using a different commercial source of siRNAs to control for off-target effects, we confirmed that knockdown of 16 of these kinases robustly induced STBS reporter activity (Fig. 1e) . Loss of 13 of these kinases also led to YAP nuclear accumulation even in high-density conditions where Hippo signalling is typically activated ( Fig. 1f and Supplementary Fig. 1a ). To further characterize these hits, we evaluated their effects on YAP phosphorylation at Ser 127, as this is a highly conserved direct-substrate site for LATS1/2 and is one of the best characterized biochemical markers for Hippo-mediated YAP inactivation 14 . Silencing of 8 of the 16 kinases resulted in decreases in YAP S127 phosphorylation ( Fig. 1g and Supplementary  Fig. 1b ), indicating that some of these molecules regulate YAP activity independently of Hippo.
A R T I C L E S
Interestingly, four of the validated kinase hits (MAP2K7, MAP3K9, MAP4K4, MAP4K5) are part of an activating network of the c-Jun amino-terminal kinase (JNK) branch of the mitogen-activated kinase (MAP) pathway, a stress-activated cascade implicated in compensatory growth and tumorigenesis 15 . Silencing of these kinases does not lead to a reduction in YAP Ser 127 phosphorylation, indicating an alternative mode of YAP regulation ( Supplementary Fig. 1b) . A targeted analysis using RNA-interference (RNAi) and small-molecule manipulation confirmed that only the JNK arm of the MAP kinase pathway controlled YAP/TEAD reporter activity ( Supplementary Fig. 1c,d ). Although the role of JNK signalling in cancer is complex, our data support emerging findings suggesting that JNK activators are tumour suppressors, and implicate Hippo-YAP signalling as a downstream mechanism 16, 17 . The ephrin receptor EPHA7 (Fig. 1d-g ), implicated in providing cell-positioning cues during development and mutated in lung cancer and lymphomas 18, 19 , also regulates YAP activity. Intriguingly, other ephrin-type A receptors (EPHA4, EPHA5 and EPHA8; Supplementary Table 2) are also found to enhance STBS activity, indicating an important crosstalk between ephrin signalling and Hippo. We also identify MAGI1 (Fig. 1e-g suppressive kinase also mutated in multiple human cancers 10, 20 . GAK, a protein involved in clathrin-mediated endocytosis is also a hit 21 , as are the microtubule regulating kinases NEK4 and TESK1 (ref. 22). Among the other regulators, a recently described Hippo-regulating kinase, TAOK1, was also identified ( Fig. 1 and Supplementary Fig. 1a ,b and Table 1 
LKB1 regulates YAP through MST/LATS
We were particularly interested by the fact that YAP phosphorylation was significantly repressed by STK11 knockdown (Fig. 1e-g ). STK11, also known as LKB1, is a well-established human tumour suppressor that controls, among other things, cellular metabolism, proliferation and polarity 24 . The effect of LKB1 knockdown on YAP phosphorylation and localization was reproduced with multiple oligonucleotides and cell lines ( Supplementary Fig. 2a-d) . LKB1 knockdown also resulted in the upregulation of known YAP target genes, such as Amotl2 and Cyr61 (ref. 6 and Fig. 2a ). This transcriptional response was entirely YAP-dependent, as endogenous target gene and reporter responses were suppressed in YAP/LKB1 double-knockdown cells (Fig. 2a,b and Supplementary Fig. 2e ). To further demonstrate a regulatory role of LKB1 upstream of YAP we used an engineered intestinal epithelial cell line (W4) in which LKB1 activity could be induced following treatment with doxycycline 25 (Dox). Dox-dependent LKB1-activity is evidenced by polarization and actin cytoskeleton rearrangements (Fig. 2c,d ). Whereas YAP is predominantly nuclear at low cell densities, stimulation of LKB1 activity induced a striking and significant shift of YAP localization into the cytoplasm and actin cap of polarized cells (Fig. 2c,d ). Consistent with this, we observed a significant reduction of YAP/TEAD transcriptional activity in Dox-treated cells ( Supplementary  Fig. 2f ). Our results are consistent with a recent report indicating YAP activation in LKB1-mutant cell lines 26 . We next determined whether LKB1 acts through the canonical Hippo kinases to regulate YAP. We observed increased MST1 activity, as measured by phosphorylation and the presence of a cleaved MST1 catalytic fragment following LKB1 activation in W4 cells (Fig. 2e) . Similarly, LKB1 activation led to a marked increase in phosphorylation of Thr 1079 in LATS1/2 (Fig. 2f ). This residue marks LATS1/2 activation by MST1/2 and its co-activator SAV1 (ref. 14). Correspondingly, LKB1 silencing led to loss of LATS1/2 Thr 1079 phosphorylation (Fig. 2g) . To confirm that LKB1 is important for MST1/2 activation, we used a mouse model in which Lkb1 was deleted in the liver using Ad-Cre. In agreement with MST1/2 loss-of-function phenotypes 9 , Lkb1 deletion resulted in hepatomegaly and increased hepatocyte proliferation (Supplementary Fig. 2g ). As predicted, we also observed a significant decrease in the amount of cleaved and phosphorylated MST1 peptide in Lkb1-deficient livers ( Fig. 2h and Supplementary Fig. 2h ) and upregulation of YAP target genes (Fig. 2i ). Supporting our findings that LKB1 acts upstream of the Hippo kinases, we find that expression of LATS1/2 and its co-activator MOB1 rescues the increase in YAP/TEAD transcriptional activity following knockdown of LKB1 (Fig. 2j) . Furthermore, knockdown of MST1/2 or LATS1/2 in Dox-treated W4 cells significantly suppresses the LKB1-mediated shift in YAP subcellular localization ( Fig. 2k and Supplementary Fig. 2i-j) . Supporting a regulatory role, we find that endogenous and overexpressed LKB1 can strongly interact with both LATS1 and MST1 in co-immunoprecipitation experiments ( Fig. 2l and Supplementary Fig. 2k -l).
LKB1 acts upstream of MARKs to regulate YAP
To shed light on a possible mechanism for regulation, we performed in vitro kinase assays and mass spectrometry analyses to determine whether MST1 or LATS2 could be direct targets of LKB1. Our results found no evidence for LKB1-mediated phosphorylation at potential consensus sites in either MST1 or LATS2, thus suggesting that the LKB1 effect on these kinases was indirect. We then performed a siRNA mini-screen evaluating most known downstream targets of LKB1 (ref. 27), including AMPK and mTOR, commonly implicated in growth suppression by LKB1, for their ability to regulate the STBS reporter. This screen revealed that three members of the MARK family (MARK1, 3 and 4; hereafter referred to as MARKs) were able to modulate TEAD-reporter activity (Fig. 3a) . These kinases are also hits in our primary kinome screen if lower hit thresholds are selected (Supplementary Table 2 ). The effect of MARK knockdown was reproduced across several cell types and with multiple oligonucleotides ( Fig. 3b and Supplementary Fig. 3a) , and its effect on TEAD-reporter activity was also suppressed with concomitant knockdown of YAP ( Supplementary Fig. 3b ). Loss of MARK4 also results in enhanced YAP nuclear localization (Fig. 3c) , and a decrease in LATS and YAP phosphorylation (Fig. 3d) . Suggesting that MARKs also act upstream of the Hippo kinases, overexpression of LATS and MOB1 can fully suppress the MARK4 knockdown effect on TEAD-reporter activity ( Fig. 3e and Supplementary Fig. 3c ). To ascertain whether MARKs were functionally downstream of LKB1, we knocked down MARKs in LKB1-induced W4 cells. Dox addition to W4 cells leads to MARK1 activation 27 ( Supplementary Fig. 3d ), and silencing of MARKs in this context resulted in a significant loss of cytoplasmic YAP translocation ( Fig. 3f and Supplementary Fig. 3e-f) . Combined, these data demonstrate that LKB1 is exerting its effects on the Hippo pathway through its direct substrate, the MARKs. 
MARKs regulate SCRIB localization and Hippo kinase activity
MARKs are also known as the PAR-1 family of proteins and have been implicated in the regulation of cell polarity and microtubule dynamics through different mechanisms 28 . In Drosophila, the PAR-1 orthologue has been shown to phosphorylate and regulate localization of Discs large 29 (DLG), a member of the basolateral polarity complex also consisting of Lethal giant larvae (LGL) and Scribble 30,31 (SCRIB). Proper localization of SCRIB is required for Hippo pathway activity in both Drosophila and mammalian cells [32] [33] [34] . Thus, we posited that LKB1 could be regulating Hippo-YAP activity through regulation of the basolateral polarity complex by the MARKs. Indeed, we find that MARKs knockdown results in mislocalization of SCRIB ( Fig. 4a and Supplementary Fig. 4a ), and reduction of SCRIB protein ( Supplementary Fig. 4b-c) . Demonstrating a direct role for LKB1 and MARKs in the localization of SCRIB, Dox-mediated activation of LKB1 in W4 cells results in SCRIB recruitment to the cellular membrane and the actin cap (Fig. 4b) . Knockdown of MARKs in this context reduces the sub-cellular localization shift of SCRIB (Fig. 4b) . As predicted, SCRIB knockdown also leads to an increase in TEAD-reporter activity and a decrease in YAP phosphorylation ( Fig. 4c and Supplementary  Fig. 4e ). Importantly, knockdown of SCRIB in LKB1-activated W4 cells significantly rescues the shift of YAP localization to the cytoplasm and actin cap ( Fig. 4d and Supplementary Fig. 4f-h ), indicating that SCRIB is critical for LKB1-mediated regulation of YAP. Moreover, co-immunoprecipitation experiments demonstrate that endogenous MARK1 or overexpressed MARK4 can be detected in a complex with LKB1, MST1, LATS1 and SCRIB ( Fig. 4e and Supplementary  Fig. 4i ), indicating the existence of a Hippo regulatory protein complex. It has been proposed that association of SCRIB with MST1/2 is important for the activation of the Hippo cascade 34 . We find that this association is highly dependent on MARKs ( Fig. 4f and Supplementary  Fig. 4j ), as their loss impairs the interaction of both MST1/2 and LATS1/2 with SCRIB.
YAP activation is a hallmark of LKB1-mutant tumours
Lkb1 germline mutations are associated with Peutz-Jeghers syndrome (PJS), an inherited disorder in which patients develop intestinal polyps and are at higher risk for developing multiple malignancies 35 . Lkb1 alterations are also present in many types of sporadic epithelial cancer, particularly lung and pancreatic carcinomas 35 . Loss of Lkb1 in mice is associated with more aggressive and metastatic potential of lung tumours 36 . To corroborate our in vitro observations, we evaluated the status of Hippo signalling in lung tumours derived from mice carrying an activating K-Ras mutation (K) or the KRas transgene and concomitant Lkb1 deletion (KL). Strikingly, we find that stage-matched KL adenocarcinomas were strongly positive for nuclear YAP in contrast to K tumours, which exhibit predominantly cytoplasmic and diffuse YAP localization (Fig. 5a ). To further assess the extent of YAP transcriptional activity in Lkb1-null tumours, we carried out gene set enrichment analysis to examine the enrichment of a YAP transcriptional signature derived in our laboratory ( Supplementary Fig. 5a ). Gene set enrichment analysis demonstrates a highly significant enrichment of this YAP signature in KL tumours (Fig. 5b) . Furthermore, biochemical analyses of tumour nodules also demonstrate decreased MST1/2 and YAP Ser 127 phosphorylation in the KL genotype (Fig. 5c) . Furthermore, as predicted from our model, SCRIB localization is markedly altered and its expression reduced in KL tumours (Fig. 5d) . We also evaluated YAP status in a model of pancreatic neoplasia derived from tissue-specific deletion of Lkb1. Consistent with the lung tumour data, Lkb1-null pancreatic ductal adenocarcinomas exhibit robust YAP nuclear localization compared with control tissue (Fig. 5e) . Moreover, we find that gastrointestinal polyps of human PJS patients exhibit an increase in nuclear YAP localization in both epithelial and smooth muscle cells compared with normal colon or juvenile polyposis polyps carrying SMAD4 mutations ( Fig. 5f and Supplementary Fig. 5b ). Examination of a malignant ductal breast adenocarcinoma and metastatic liver disease that developed in a PJS patient further revealed strong YAP nuclear accumulation in the tumour (Fig. 5g,h ). Taken together, these data show that genetic deletion of Lkb1 in both murine and human tissue leads to enhanced nuclear YAP activity.
YAP is functionally important downstream of LKB1
We next investigated functionally whether YAP acted downstream of LKB1 in tumour suppression. Using W4 cells, we found that inducible LKB1 activation has a powerful growth suppressive function in vitro ( Fig. 6a and Supplementary Fig. 6a ), and in xenografts ( Fig. 6b and Supplementary Fig. 6b ). However, expression of a YAP-S217A mutant protein is able to significantly overcome all of LKB1 tumour suppressive effects (Fig. 6a,b and Supplementary Fig. 6a,b) . Silencing of either LATS2 or SCRIB also rescues growth suppression by LKB1 activation (Fig. 6d-f and Supplementary Fig. 6c,d ). To determine whether we could reverse the effects of LKB1 loss by manipulating YAP-expression levels, we developed a Dox-inducible YAP short hairpin RNA (shRNA) A549 cell line (Supplementary Fig. 7a ). A549 is a lung cancer cell line mutant for LKB1 widely used in tumour growth and metastasis assays 36 . In both a soft-agar colony-formation assay, and in vivo metastatic assays, we find that YAP depletion following Dox-treatment reduces the number and/or size of colonies and tumours (Fig. 7a,b and Supplementary Fig. 7a-c) . Lung adenocarcinoma cell lines that are wild type for LKB1 and expressed lower levels of YAP were insensitive to YAP modulation ( Supplementary Fig. 7d-f) . Finally, we used Ad-Cre infection in mice to demonstrate that conditional deletion of Yap1 suppresses the liver overgrowth phenotype (Fig. 7c,d ) and hepatocyte hyperplasia observed following acute deletion of Lkb1 (Fig. 7e,f and Supplementary Fig. 7g ). Together these data provide multiple lines of evidence that Hippo-YAP is a functionally critical pathway downstream of LKB1.
DISCUSSION
One important question in the Hippo-YAP field relates to the upstream signals that regulate the Hippo kinases. Our studies here have identified many molecules and pathways that might impinge on Hippo activity and growth control. As many of these kinases are also mutated in human cancer, their identification as regulators of YAP might provide a molecular explanation for the observations that YAP is highly active in numerous epithelial tumours, where mutations in the canonical Hippo components are not found.
The tumour suppressive function of LKB1 has primarily been linked to its ability to regulate cellular metabolism through AMPK activation 37 . LKB1 is linked to mTOR through the sequential activation of AMPK and the tumour suppressor TSC2, whose activation leads to suppression of mTOR activity 38 . It has been shown that polyps from PJS patients show upregulated mTOR activity, as do pancreata, cardiomyocytes and endometria of Lkb1-deficient mice. Treatment of endometrial LKB1-mutant adenocarcinomas with rapamycin and mTOR inhibitor, leads to regression of these tumours, supporting a functional role for mTOR downstream of LKb1 (ref. 38). Our studies here suggest that LKB1 can also exert its tumour suppressive effects through activation of a PAR-1-mediated polarity axis that controls the Hippo signalling pathway. Our data demonstrating that YAP loss could completely rescue growth phenotypes mediated by LKB1 loss in vivo suggest that this might a central mechanism. On this note, it has been shown that YAP can lead to mTOR activity through transcriptional activation of miR-29. Thus, YAP activation due to LKB1 alterations could also lead to mTORC1 activation.
Our data provide insight into a signalling axis downstream of LKB1 and PAR-1 kinases that regulates the interaction of the Hippo kinases with SCRIB and perhaps other components of the basolateral polarity complex. MARKs can also lead to changes in polarity by antagonizing the PAR-3/PAR-6 polarity complex 39 . This complex is localized apically whereas PAR-3 lacking PAR-1 phosphorylation results in ectopic lateral mislocalization. Under normal conditions, the lateral exclusion of PAR-3/PAR-6 by PAR-1 also cooperates with Crumbs to restrict Par-3 localization, and loss of both pathways disrupts epithelial polarity 39 . The literature supports that the Hippo pathway is indeed regulated by these polarity complexes 32, 40 . Whether Par-3, Par-6, Crumbs and other substrates of Par-1/MARKs are also involved in controlling SCRIB remains to be investigated. Similarly, a connection between Hippo-YAP signalling and the actin cytoskeleton has recently been demonstrated 41 . Considering that LKB1 and SCRIB have effects on the actin cytoskeleton 42, 43 , it is possible that actin fibre regulation could be an additional mechanism by which LKB1 modulates YAP activity. LKB1 is then a candidate upstream regulator of the multiple inputs that impinge on YAP activity. Collectively, these data suggest that manipulation of the Hippo signalling pathway should now be evaluated for the treatment of LKB1 mutant cancers.
METHODS
Methods and any associated references are available in the online version of the paper. (Fig. 1d) . To ensure limited edge effects, outer rows and columns were not used and instead were occupied by cell media. At 96 h post-transfection, HEK293T cells in negative control wells are confluent. Plates are subsequently trypsinized in 20 µl of trypsin/EDTA and inactivated in 30 µl of DMEM/10% FBS and analysed by flow cytometry using Texas red and GFP (HTS, BD LSRII) to obtain the mean fluorescent intensity of each cell. Data were collected and analysed using FACSDiva 6.0 (BD Biosciences). For followup work, individual oligonucleotides targeting YAP (s20366), LATS1 (s17392), LATS2 (s25503), MST1 (s13570), MST2 (s13567), SCRIB (s23970), MARK1 (#s8512), MARK4 (s33718) and NF2 (s194647), all from Ambion, were used.
M E T H O D S
Hit selection. Positive hits for each gene were identified as follows. Z -scores and fold changes were calculated for each oligonucleotide when compared with the negative control for each individual 96-well plate. Rigorous hit selection was performed by eliminating data that did not reproduce in at least two out of the three experiments for each oligonucleotide. Subsequently, these data were further filtered to identify oligonucleotides that reproducibly have a Z -score > 2 and fold change > 4. The final hit selection is based on the mean Z -score values and mean fold changes of each oligonucleotide for each gene, and if two or more oligonucleotides for each gene met these thresholds.
Immunofluorescence. Cells were seeded in a 24-well plate on sterilized glass coverslips overnight and then fixed in 4% paraformaldehyde/PBS for 10 min at room temperature, followed by three washes in PBS. Cells are permeabilized in 0.01% Triton/PBS for 1 min, followed by three washes in 0.01% Tween/PBS. Cells were then incubated in blocking buffer (0.5% FBS/PBS/0.01%Tween) for 1 h at room temperature and then incubated overnight at 4 Tissues were embedded in paraffin and 5 µm sections were mounted on positively charged slides. Tissues were deparaffinized and antigen retrieval was performed in pH 6.0 citrate buffer for 30 min at 95 • C. ABC tissue staining was performed by using a modified protocol from Vector Laboratories VECTASTAIN Elite ABC kit (#PK-6101, #PK-2200). Briefly, the endogenous peroxidase was blocked by incubation in 0.3% hydrogen peroxide for 1 min. Sections were blocked in rabbit sera followed by primary antibody incubation overnight at 4 • C (YAP 1:100, Cell Signaling #4912; Scribble 1:400, Santa Cruz #1049; Ki67 1:50, DAKO MIB-5). Sections were washed and then incubated with HRP-conjugated secondary antibody (30 min; 20 • C), and developed with 3,3 -diaminobenzidine tetrahydrochloride (DAB)/H 2 O 2 . Counterstaining was done with haematoxylin and samples were washed, dehydrated, and mounted with Vectamount (Vector Labs #H-5000). Data obtained for immunohistochemistry analyses were repeated using sections from the same tissue and/or from amongst the same genotypic group. Representative images shown are from tissues that exhibit the least signal/noise background staining and represent most of the tissues that were analysed; however, there are some tissues that were stained that exhibited either more intense or weaker staining, which are not shown as they represented the minority of tissues examined.
Immunoblotting. Cell lines and tissues were collected, and processed for western blotting by solubilizing extracts in lysis buffer (50 mM Tris, 100 mM NaCl, protease inhibitor cocktail (Roche #04693159001) and phosSTOP (Roche, # 04906837001)). For standard immunodetection of proteins, 20 g of protein was used. For detection of phospho-proteins 30 g of total protein lysate was used. Protein lysates were then resolved by PAGE under reducing conditions (4-12% SDS-PAGE Bis-Tris gels; MOPS buffer system; Invitrogen; NuPAGE-MOPS system). The gels were blotted onto PVDF or nitrocellulose papers and blocked in either milk for standard antibodies or BSA for phospho-antibodies (phospho-antibodies blocked in PBS, 5% w/v BSA, 0.1% Tween-20 at dilutions: pYAP 1:1,000, Cell Signaling #4911; pMST1/2 1:1,000, Cell Signaling #3681; pLATS1/2 1:1,000, Cell Signaling #9153; pMARK 1:500, Cell Signaling #4836; pACC 1:1,000, Cell Signaling #3661; standard antibodies blocked in TBS-T, 5% w/v milk at dilutions: MST1 1:500, Cell Signaling #3682; Lats1 1:500, Cell Signaling #3477; MARK4 1:1,000 Cell Signaling #4834; LKB1 1:1,000 Santa Cruz sc-32245; Scribble 1:5,000, Santa Cruz sc-11049; MARK1 1:1,000 Cell Signaling #3319; AMPK 1:2,500, Cell Signaling #2603) for 1 h at room temperature, followed by incubation in primary antibodies diluted in blocking buffer. Unless otherwise stated, all primary antibody incubation steps were performed overnight at 4 • C. After washing in TBS-T, antigens were detected using HRP-conjugated secondary antibodies (1:20,000 in TBS-T: Thermo #32430, #32460, Santa Cruz #sc-2020), and visualized using enhanced chemoluminescence (Thermo, #34096). Immunoblots shown are representative of experiments that were repeated and reproduced at least three independent times. For some challenging experiments and antibodies, the representative blots are ones that show the least nonspecific background and have a low signal-to-noise ratio.
Cell lines. LS174T, HEK293T, DLD1, MCF7 and HaCaT cells were cultured in DMEM + 10% FBS in 5% CO 2 , >95% humidity. A549 cells were cultured in RPMI-1640 supplemented with 2 mM l-glutamine and 10% FBS. The LS174T-W4 clone cell line was a gift from H. Clevers (Utrecht Institute, Netherlands). Other cell lines were acquired from the American Type Culture Collection (Manassas).
Soft-agar colony-formation assay. The base agar consisted of low-melting-point 0.6% agar dissolved in RPMI-1640 (Life Technologies, # 31800-022) or DMEM (Life Technologies # 12100046), 10% FBS and 1% penicillin/streptomycin. Base agar was allowed to set for at least 1 h before plating of the top agar. The top agar consisted of approximately 250 cells resuspended in 0.3% low-melting-point agar dissolved in RPMI or DMEM, 10% FBS, 1X penicillin/streptomycin in a well of a 6-well plate. Samples were incubated for 4 weeks following seeding and then stained with 0.1% crystal violet in 10% ethanol for 20 min. Wells were destained in distilled water 5 times or until the decanted water ran clear before imaging.
In vitro proliferation assay. A colorimetric MTS assay (Promega, # G5430, Madison) was used to determine the proliferation rate for different cell lines. Experiments were done following the manufacturer's instructions. Briefly, 1,000 cells per well were cultured in triplicate into 96-well plates and incubated for 0-7 days. At the time of culture and each day for a total of 7 days, a plate was analysed by colorimetric reading (absorption of light at 450 nm). For all experiments involving Ad-Cre-mediated deletion, female mice of approximately 5-6 weeks of age were used. Ad-Cre administration was performed between 2-4 weeks of age. Xenograft assays were performed in 5-week-old male Nu/J mice (JAX Labs, B6.Cg-Foxn1 nu /J), using 1 × 10 6 cells 100 µl −1 volume of Matrigel (BD Biosciences). Metastasis assays were performed in 5-week-old male NOD/SCID mice (JAX Labs, NOD.CB17-Prkdc scid /J) using 1 × 10 6 cells 100 µl −1 volume of PBS injected intravenously. For induction in the liver, 100 µlof Ad-Cre was introduced intravenously at 1 × 10 9 pfu per mouse (Ad5CMVCre, University of Iowa, GTVC) 45 . No statistical method was used to predetermine sample size for treatment groups. There was also no requirement for animal randomization during the course of the animal studies.
Tissue samples. We studied formalin-fixed paraffin-embedded tissue-biopsy sections of diagnosed PJS and juvenile polyposis patients with confirmed mutations in LKB1, SMAD4 and PTEN respectively. Studies with patients' samples at Boston Children's Hospital were covered under IRB-CRM09-12-0660. Four days after transfection, confluent cell culture was collected for RNA extraction with the Trizol reagent (Invitrogen). RNA quality assessment, cDNA synthesis, probe generation, array hybridization and scanning were carried out by Boston Children's Hospital Molecular Genetics Microarray Core Facility. Data sets were analysed with the online microarray analysis software GenePattern (Broad Institute) with default settings. Differentially expressed genes were defined as those with at least a twofold change in NF2/LATS2 double-knockdown cells and a P value smaller than 0.05. To generate a generic Hippo target gene signature, genes upregulated in all three NF2/LATS2 double-knockdown cell lines were combined, and those without a gene symbol were eliminated from the list. For gene set enrichment analysis, we used a data set from published gene expression profiles of lung adenocarcinomas developed in Kras G12D , Kras G12D Lkb1 f/-or Kras G12D Lkb1 f/f mouse models 36 . The enrichment analysis was performed in the GSEA software available from the Broad Institute with the default settings.
Microarray accession numbers.
Microarray data generated for this study have been deposited in the GEO database under accession number GSE49384. The published microarray data set 36 re-analysed in this study is available from the GEO database under accession number GSE6135.
Statistical analyses.
No statistical method was used to predetermine sample size.
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